Now and the Future: Medications Changing the Landscape of Cardiovascular Disease and Heart Failure Management

Area of Science:

• Cardiology
• Endocrinology
• Nephrology

Background:

• Cardiovascular diseases (CVDs) are a leading cause of global mortality.
• Increasing comorbidity of CVD, Type 2 Diabetes (T2DM), chronic kidney disease (CKD), and heart failure (HF) presents treatment challenges, particularly in aging populations.

Purpose of the Study:

• To review three emerging drug classes—sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and glucagon-like peptide 1 receptor agonists (GLP-1RAs)—for managing CVD and HF.
• To explore the evidence base and future clinical implications of these agents in mainstream medical therapy.

Main Methods:

• Review of current evidence for SGLT2 inhibitors, GLP-1RAs, and non-steroidal MRAs in heart failure (HF) and cardiovascular disease (CVD) management.
• Analysis of their prognostic benefits in patients with T2DM and CKD.

Main Results:

• SGLT2 inhibitors, GLP-1RAs, and non-steroidal MRAs are emerging as significant therapeutic options for CVD and HF.
• These drug classes are being incorporated into treatment guidelines and demonstrate benefits for patients with comorbid T2DM and CKD.
• Potential for primary care to lead CVD risk stratification using these agents with tailored regimens.

Conclusions:

• SGLT2 inhibitors, GLP-1RAs, and non-steroidal MRAs represent a significant advancement in treating complex cardiovascular conditions.
• These therapies offer a promising future for integrated patient care, addressing multimorbidity in CVD, HF, T2DM, and CKD.